APO Research
Talk to an analyst

APO RESEARCH · REPORT

mRNA Platform

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global mRNA Platform Market Outlook and Growth Opportunities 2026

30 December 2025199 pages

Choose your research edition.

Industry ResearchmRNA Platform Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA Platform Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal mRNA Platform Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA Platform Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA Platform Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global mRNA Platform market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for mRNA Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for mRNA Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for mRNA Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the mRNA Platform market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the mRNA Platform market include Arcturus Therapeutic, Argos Therapeutics, BioNTec, CureVac, Etherna, Ethris, Translate Bio, GlaxoSmithKline and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global mRNA Platform market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of mRNA Platform and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents mRNA Platform revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global mRNA Platform market.

mRNA Platform Segment by Company

Arcturus Therapeutic

Argos Therapeutics

BioNTec

CureVac

Etherna

Ethris

Translate Bio

GlaxoSmithKline

Pfizer

mRNA Platform Segment by Type

Infectious Disease Vaccines

Cancer Vaccines

mRNA Platform Segment by Application

Infectious Disease

Cancer

mRNA Platform Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global mRNA Platform status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the mRNA Platform key companies, revenue, market share, and recent developments.

3. To split the mRNA Platform breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions mRNA Platform market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify mRNA Platform significant trends, drivers, influence factors in global and regions.

6. To analyze mRNA Platform competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Platform.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Platform industry.

Chapter 3: Detailed analysis of mRNA Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of mRNA Platform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of mRNA Platform in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. mRNA Platform Industry Trends Table 2. mRNA Platform Industry Drivers Table 3. mRNA Platform Industry Opportunities and Challenges Table 4. mRNA Platform Industry Restraints Table 5. Global mRNA Platform Revenue by Company (US$ Million) & (2021-2026) Table 6. Global mRNA Platform Revenue Share by Company (2021-2026) Table 7. Global mRNA Platform Company Ranking, (2024-2026) & (US$ Million) Table 8. Global mRNA Platform Key Company Manufacturing Base & Headquarters Table 9. Global mRNA Platform Company, Product Type & Application Table 10. Global mRNA Platform Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global mRNA Platform by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Infectious Disease Vaccines Table 15. Significant Companies of Cancer Vaccines Table 16. Global mRNA Platform Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global mRNA Platform Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global mRNA Platform Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global mRNA Platform Sales Value Share by Type (2021-2026) Table 20. Global mRNA Platform Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Infectious Disease Table 22. Significant Companies of Cancer Table 23. Global mRNA Platform Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global mRNA Platform Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global mRNA Platform Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global mRNA Platform Sales Value Share by Application (2021-2026) Table 27. Global mRNA Platform Sales Value Share by Application (2027-2032) Table 28. Global mRNA Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global mRNA Platform Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global mRNA Platform Sales Value Share by Region (2021-2026) Table 31. Global mRNA Platform Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global mRNA Platform Sales Value Share by Region (2027-2032) Table 33. Global mRNA Platform Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global mRNA Platform Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global mRNA Platform Sales Value Market Share by Country (2021-2026) Table 36. Global mRNA Platform Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global mRNA Platform Sales Value Market Share by Country (2027-2032) Table 38. Arcturus Therapeutic Company Information Table 39. Arcturus Therapeutic Business Overview Table 40. Arcturus Therapeutic mRNA Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Arcturus Therapeutic mRNA Platform Product Portfolio Table 42. Arcturus Therapeutic Recent Development Table 43. Argos Therapeutics Company Information Table 44. Argos Therapeutics Business Overview Table 45. Argos Therapeutics mRNA Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Argos Therapeutics mRNA Platform Product Portfolio Table 47. Argos Therapeutics Recent Development Table 48. BioNTec Company Information Table 49. BioNTec Business Overview Table 50. BioNTec mRNA Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. BioNTec mRNA Platform Product Portfolio Table 52. BioNTec Recent Development Table 53. CureVac Company Information Table 54. CureVac Business Overview Table 55. CureVac mRNA Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. CureVac mRNA Platform Product Portfolio Table 57. CureVac Recent Development Table 58. Etherna Company Information Table 59. Etherna Business Overview Table 60. Etherna mRNA Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Etherna mRNA Platform Product Portfolio Table 62. Etherna Recent Development Table 63. Ethris Company Information Table 64. Ethris Business Overview Table 65. Ethris mRNA Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Ethris mRNA Platform Product Portfolio Table 67. Ethris Recent Development Table 68. Translate Bio Company Information Table 69. Translate Bio Business Overview Table 70. Translate Bio mRNA Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Translate Bio mRNA Platform Product Portfolio Table 72. Translate Bio Recent Development Table 73. GlaxoSmithKline Company Information Table 74. GlaxoSmithKline Business Overview Table 75. GlaxoSmithKline mRNA Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. GlaxoSmithKline mRNA Platform Product Portfolio Table 77. GlaxoSmithKline Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer mRNA Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Pfizer mRNA Platform Product Portfolio Table 82. Pfizer Recent Development Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. mRNA Platform Product Image Figure 2. Global mRNA Platform Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA Platform Market Size (2021-2032) & (US$ Million) Figure 4. Global mRNA Platform Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Infectious Disease Vaccines Image Figure 8. Cancer Vaccines Image Figure 9. Global mRNA Platform Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global mRNA Platform Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global mRNA Platform Sales Value Share by Type (2021-2032) Figure 12. Infectious Disease Image Figure 13. Cancer Image Figure 14. Global mRNA Platform Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global mRNA Platform Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global mRNA Platform Sales Value Share by Application (2021-2032) Figure 17. Global mRNA Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global mRNA Platform Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America mRNA Platform Sales Value (2021-2032) & (US$ Million) Figure 20. North America mRNA Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe mRNA Platform Sales Value (2021-2032) & (US$ Million) Figure 22. Europe mRNA Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific mRNA Platform Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific mRNA Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America mRNA Platform Sales Value (2021-2032) & (US$ Million) Figure 26. South America mRNA Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa mRNA Platform Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa mRNA Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt mRNA Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt mRNA Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt mRNA Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Infectious Disease Vaccines
  • Cancer Vaccines
Applications
  • Infectious Disease
  • Cancer
Companies covered
  • Arcturus Therapeutic
  • Argos Therapeutics
  • BioNTec
  • CureVac
  • Etherna
  • Ethris
  • Translate Bio
  • GlaxoSmithKline
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global mRNA Platform Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global mRNA Platform Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 mRNA Platform Market Dynamics
  1. 2.1 mRNA Platform Industry Trends
  2. 2.2 mRNA Platform Industry Drivers
  3. 2.3 mRNA Platform Industry Opportunities and Challenges
  4. 2.4 mRNA Platform Industry Restraints
3 mRNA Platform Market by Company
  1. 3.1 Global mRNA Platform Company Revenue Ranking in 2025
  2. 3.2 Global mRNA Platform Revenue by Company (2021-2026)
  3. 3.3 Global mRNA Platform Company Ranking (2024-2026)
  4. 3.4 Global mRNA Platform Company Manufacturing Base and Headquarters
  5. 3.5 Global mRNA Platform Company Product Type and Application
  6. 3.6 Global mRNA Platform Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global mRNA Platform Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 mRNA Platform Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 mRNA Platform Market by Type
  1. 4.1 mRNA Platform Type Introduction
  2. 4.1.1 Infectious Disease Vaccines
  3. 4.1.2 Cancer Vaccines
  4. 4.2 Global mRNA Platform Sales Value by Type
  5. 4.2.1 Global mRNA Platform Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global mRNA Platform Sales Value by Type (2021-2032)
  7. 4.2.3 Global mRNA Platform Sales Value Share by Type (2021-2032)
5 mRNA Platform Market by Application
  1. 5.1 mRNA Platform Application Introduction
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Cancer
  4. 5.2 Global mRNA Platform Sales Value by Application
  5. 5.2.1 Global mRNA Platform Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global mRNA Platform Sales Value by Application (2021-2032)
  7. 5.2.3 Global mRNA Platform Sales Value Share by Application (2021-2032)
6 mRNA Platform Regional Value Analysis
  1. 6.1 Global mRNA Platform Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global mRNA Platform Sales Value by Region (2021-2032)
  3. 6.2.1 Global mRNA Platform Sales Value by Region: 2021-2026
  4. 6.2.2 Global mRNA Platform Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America mRNA Platform Sales Value (2021-2032)
  7. 6.3.2 North America mRNA Platform Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe mRNA Platform Sales Value (2021-2032)
  10. 6.4.2 Europe mRNA Platform Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific mRNA Platform Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific mRNA Platform Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America mRNA Platform Sales Value (2021-2032)
  16. 6.6.2 South America mRNA Platform Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa mRNA Platform Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa mRNA Platform Sales Value Share by Country, 2025 VS 2032
7 mRNA Platform Country-level Value Analysis
  1. 7.1 Global mRNA Platform Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global mRNA Platform Sales Value by Country (2021-2032)
  3. 7.2.1 Global mRNA Platform Sales Value by Country (2021-2026)
  4. 7.2.2 Global mRNA Platform Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA mRNA Platform Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA mRNA Platform Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA mRNA Platform Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada mRNA Platform Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada mRNA Platform Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada mRNA Platform Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico mRNA Platform Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico mRNA Platform Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico mRNA Platform Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany mRNA Platform Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany mRNA Platform Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany mRNA Platform Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France mRNA Platform Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France mRNA Platform Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France mRNA Platform Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. mRNA Platform Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. mRNA Platform Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. mRNA Platform Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy mRNA Platform Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy mRNA Platform Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy mRNA Platform Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain mRNA Platform Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain mRNA Platform Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain mRNA Platform Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia mRNA Platform Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia mRNA Platform Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia mRNA Platform Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands mRNA Platform Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands mRNA Platform Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands mRNA Platform Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries mRNA Platform Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries mRNA Platform Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries mRNA Platform Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China mRNA Platform Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China mRNA Platform Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China mRNA Platform Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan mRNA Platform Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan mRNA Platform Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan mRNA Platform Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea mRNA Platform Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea mRNA Platform Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea mRNA Platform Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India mRNA Platform Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India mRNA Platform Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India mRNA Platform Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia mRNA Platform Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia mRNA Platform Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia mRNA Platform Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia mRNA Platform Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia mRNA Platform Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia mRNA Platform Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil mRNA Platform Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil mRNA Platform Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil mRNA Platform Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina mRNA Platform Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina mRNA Platform Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina mRNA Platform Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile mRNA Platform Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile mRNA Platform Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile mRNA Platform Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia mRNA Platform Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia mRNA Platform Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia mRNA Platform Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru mRNA Platform Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru mRNA Platform Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru mRNA Platform Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia mRNA Platform Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia mRNA Platform Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia mRNA Platform Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel mRNA Platform Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel mRNA Platform Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel mRNA Platform Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE mRNA Platform Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE mRNA Platform Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE mRNA Platform Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey mRNA Platform Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey mRNA Platform Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey mRNA Platform Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran mRNA Platform Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran mRNA Platform Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran mRNA Platform Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt mRNA Platform Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt mRNA Platform Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt mRNA Platform Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Arcturus Therapeutic
  2. 8.1.1 Arcturus Therapeutic Company Information
  3. 8.1.2 Arcturus Therapeutic Business Overview
  4. 8.1.3 Arcturus Therapeutic mRNA Platform Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Arcturus Therapeutic mRNA Platform Product Portfolio
  6. 8.1.5 Arcturus Therapeutic Recent Developments
  7. 8.2 Argos Therapeutics
  8. 8.2.1 Argos Therapeutics Company Information
  9. 8.2.2 Argos Therapeutics Business Overview
  10. 8.2.3 Argos Therapeutics mRNA Platform Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Argos Therapeutics mRNA Platform Product Portfolio
  12. 8.2.5 Argos Therapeutics Recent Developments
  13. 8.3 BioNTec
  14. 8.3.1 BioNTec Company Information
  15. 8.3.2 BioNTec Business Overview
  16. 8.3.3 BioNTec mRNA Platform Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BioNTec mRNA Platform Product Portfolio
  18. 8.3.5 BioNTec Recent Developments
  19. 8.4 CureVac
  20. 8.4.1 CureVac Company Information
  21. 8.4.2 CureVac Business Overview
  22. 8.4.3 CureVac mRNA Platform Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CureVac mRNA Platform Product Portfolio
  24. 8.4.5 CureVac Recent Developments
  25. 8.5 Etherna
  26. 8.5.1 Etherna Company Information
  27. 8.5.2 Etherna Business Overview
  28. 8.5.3 Etherna mRNA Platform Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Etherna mRNA Platform Product Portfolio
  30. 8.5.5 Etherna Recent Developments
  31. 8.6 Ethris
  32. 8.6.1 Ethris Company Information
  33. 8.6.2 Ethris Business Overview
  34. 8.6.3 Ethris mRNA Platform Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ethris mRNA Platform Product Portfolio
  36. 8.6.5 Ethris Recent Developments
  37. 8.7 Translate Bio
  38. 8.7.1 Translate Bio Company Information
  39. 8.7.2 Translate Bio Business Overview
  40. 8.7.3 Translate Bio mRNA Platform Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Translate Bio mRNA Platform Product Portfolio
  42. 8.7.5 Translate Bio Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline mRNA Platform Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline mRNA Platform Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer mRNA Platform Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer mRNA Platform Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst